Ameena Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ameena Patel has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Anthony Shadid
University of Illinois College of Medicine Peoria, Peoria, IL, USA
1 shared publication- Christopher S. Gondi
University of Illinois Urbana-Champaign University of Illinois Urbana-Champaign University of Illinois Chicago University of Illinois Chicago University of Illinois Chicago University of Illinois Chicago University of Illinois at Urbana-Champaign University of Illinois Chicago University of Illinois Urbana-Champaign
1 shared publication - Clare Chen
Department of Internal Medicine, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA
1 shared publication Faisal Al-Qawasmi
University of Illinois College of Medicine Peoria, Peoria, IL, USA
1 shared publication- Lusine Demirkhanyan
Department of Internal Medicine, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA
1 shared publication
Latest Publications
- Open Access
- 29 May 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (6) , 406
The Role of Mucins in Cancer and Cancer Progression: A Comprehensive Review
Mucin, a heavily glycosylated glycoprotein, serves an important function in forming protective and immune defense barriers against the exterior environment on epithelial surfaces. While secreted-type mucins are involved in mucous production, transmembrane mucins, which contain O-glycosylated tandem repeats, play a pivotal role in cellular signaling, especially in immune modulation and mediating inflammatory response. However, dysregulation in mucin expressions, such as MUC1, MUC2, MUC4, MUC5AC, and MUC16, have been observed in many cancer cells. More specifically, alterations in the expression and glycosylation of MUC1 have been associated with the upregulation of pathways involving the cell proliferation, angiogenesis, migration, and invasion of cancer cells. With mucin’s extensive involvement in cancer biology, several mucin biomarkers, such as CA125, CA19-9, and CEA, have been utilized as diagnostic and prognostic monitoring biomarkers in ovarian, pancreatic, and colon cancer. Vaccines and antibody therapy against abnormal mucin glycosylation have also been investigated for potential therapy for mucin-related cancers that are resistant to traditional chemotherapy agents. Despite the lack of specificity in mucin biomarkers and challenges in efficient drug delivery systems, the current advancement in mucin-targeted immunotherapy highlighted the pivotal potential in developing therapeutic targets to improve cancer prognosis.
- 29 May 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (6) , 406
Open AccessThe Role of Mucins in Cancer and Cancer Progression: A Comprehensive Review
Mucin, a heavily glycosylated glycoprotein, serves an important function in forming protective and immune defense barriers against the exterior environment on epithelial surfaces. While secreted-type mucins are involved in mucous production, transmembrane mucins, which contain O-glycosylated tandem repeats, play a pivotal role in cellular signaling, especially in immune modulation and mediating inflammatory response. However, dysregulation in mucin expressions, such as MUC1, MUC2, MUC4, MUC5AC, and MUC16, have been observed in many cancer cells. More specifically, alterations in the expression and glycosylation of MUC1 have been associated with the upregulation of pathways involving the cell proliferation, angiogenesis, migration, and invasion of cancer cells. With mucin’s extensive involvement in cancer biology, several mucin biomarkers, such as CA125, CA19-9, and CEA, have been utilized as diagnostic and prognostic monitoring biomarkers in ovarian, pancreatic, and colon cancer. Vaccines and antibody therapy against abnormal mucin glycosylation have also been investigated for potential therapy for mucin-related cancers that are resistant to traditional chemotherapy agents. Despite the lack of specificity in mucin biomarkers and challenges in efficient drug delivery systems, the current advancement in mucin-targeted immunotherapy highlighted the pivotal potential in developing therapeutic targets to improve cancer prognosis.
- Open Access
- 12 January 2024
- Published by Elsevier in Radiology Case Reports
- Vol. 19 (4) , 1268-1270
Encephalocele presenting with bacteremia and meningitis
- 12 January 2024
- Published by Elsevier in Radiology Case Reports
- Vol. 19 (4) , 1268-1270
Open AccessEncephalocele presenting with bacteremia and meningitis